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Abstract
Background: Ribosomal proteins are the components of ribosome, which also exhibit various
secondary functions in DNA repair, apoptosis, drug resistance and proliferation. In our previous
study of microarray, ribosomal protein L15 (RPL15) was identified as an upregulated gene in gastric
cancer.
Methods: We investigated the expression of ribosomal protein L15 in gastric cancer and the effect
of RPL15 on proliferation of gastric cancer.
Results: It was found that the expression of RPL15 was markedly up-regulated in gastric cancer
tissues. RPL15 was also highly expressed in gastric cancer cell lines AGS, MKN45, MKN28,
SGC7901 and KATOIII. Inhibition of RPL15 expression by siRNA vector transfection suppressed
the growth of SGC7901 cells significantly, which was independent of the expression of Cyclin D1
and B1. Down-regulation of RPL15 expression inhibited SGC7901 cell growth in soft agar and its
tumorigenicity in nude mice.
Conclusion: RPL15 promotes cell proliferation and may be a potential target for anticancer
therapy of gastric cancer.
Background
Gastric cancer is the second most common cause of cancer
death worldwide. Environmental and genetic factors are
both important in gastric carcinogenesis [1,2]. In recent
years, knowledge about the molecular features of gastric
carcinoma has increased rapidly. Loss of heterozygosity
(LOH) on loci of chromosomes 1, 5, 7, 12, 13 and 17 were
frequently identified in advanced gastric carcinomas [3].
Genetic alterations such as activation of oncogenes and
inactivation of tumor suppressor genes could often be
found in gastric cancer. It was believed that mutation or
amplification of oncogenes c-ras, c-erbB-2, K-sam, c-met,
and c-myc and inactivation of tumor suppressor genes
p53, adenomatosis polyposis coli (APC), deleted in color-
ectal carcinomas (DCC), and retinoblastoma (RBI) are
related to the development of gastric cancer. These genes
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are the potential prognostic markers to predict progres-
sion and metastasis of gastric cancer [3-5].
Recent studies have shown that comprehensive analysis of
gene expression patterns can identify new molecules dis-
criminating gastric cancer from normal gastric mucosa.
This technique was also be used to distinguish tumor sub-
groups and identify genes whose expression may be corre-
lated with disease classification, early detection,
prognostication as well as progression of gastric cancers
[6-8]. In our previous study, we compared the gene
expression profiling of two gastric cancer tissues with their
corresponding nontumorous tissues and found that the
expression levels of ribosomal protein L15 (RPL15) in
gastric cancer tissues increased 2.8- and 4.7-fold com-
pared to those of their controls respectively (data not pub-
lished). RPL15 has also been shown to be overexpressed
in some esophageal tumors compared to normal matched
tissues [9]. So it is interesting to see whether RPL15 is
really highly expressed in gastric cancer and the effect of
RPL15 on the malignant phenotype of gastric cancer. In
this study, we have examined the expression in gastric can-
cer tissues and cell lines with the polyclonal antibody
raised by ourselves. The effect of RPL15 on the growth of
gastric cancer cell line SGC7901 was also investigated.
Methods
Tissue collection
For immunostaining of RPL15, tissue arrays was pur-
chased from Cybrdi Co. (Chaoying Biotechnology Co.,
Xi'an, China), which contained 46 sections from normal
gastric mucosa, gastric adenocarcinoma and adjacent
nontumorous tissues respectively. For Western blotting,
gastric cancer and adjacent nontumorous tissues were
obtained from 12 patients who underwent surgery at the
Department of General Surgery in our hospital. All cases
of gastric cancer and normal gastric mucosa were clinically
and pathologically proved. The protocols used in the stud-
ies were approved by the Hospital's Protection of Human
Subjects Committee. Patients having fresh surgical tissue
for the study signed informed consent.
Cell lines and animals
Gastric cancer cell lines AGS, MKN45, MKN28, SGC7901,
KATOIII, and SV40-transformed immortal gastric epithe-
lial cell GES-1 were preserved in our department. Cells
were routinely cultured in RPMI 1640 medium (Life Tech-
nologies, Inc., Gaithersburg, MD) supplemented with
10% fetal calf serum in a 37°C humidified incubator with
a mixture of 95% air and 5% CO2. BALB/c nude mice, 4
to 6 weeks old, were provided by Shanghai Cancer Insti-
tute for the in vivo tumorigenicity study. The experiment
was performed along established, institutional animal
welfare guidelines concordant with NIH species criteria.
Antibody
Polyclonal antibodies were prepared against a peptide (C)
RVRCWQYRQLSALHR from the sequence of RPL15. Anti-
bodies were commercially prepared by immunization of 2
rabbits (Biosynthesis Biotechnology Co., Beijing, China).
The antibody was affinity purified against the peptide on
a Sulfolink column (Pierce) and used at 2 µg/ml and 6 µg/
ml in western blot and immunohistochemistry respec-
tively.
Immunohistochemistry
Tissue arrays were dewaxed, rehydrated, incubated in 10%
normal goat serum and 0.3% Triton X-100 in PBS for 1 hr
and then incubated with anti-RPL15 antibody. The arrays
were washed in PBS 3 times for 5 min each. The tissues
were incubated in biotin-labeled goat anti-mouse serum
(1:200) for 30 min, rinsed with PBS and incubated with
avidin-biotin-peroxidase complex for 1 hr. The signal was
detected using 3,3-diaminobenzidine as the chromogen.
Only cells with brown-colored cytoplasmic staining were
considered as positive. Result was evaluated by formula as
described previously [10]: the staining score = the inten-
sity of immunoreactivity (IR) × the proportion of posi-
tively staining cells. The intensity of IR was stratified into
4 categories: 0, no IR; 1, weak IR; 2, moderate IR and 3,
strong IR. The proportion of positive cells was classified
into 4 groups: 0, 0–5% tumor cells exhibiting IR; 0.33, 5–
33% of the tumor cells exhibiting IR; 0.67, 33–67% of the
tumor cells exhibiting IR and 1, 67–100% of the tumor
cells exhibiting IR.
Plasmid construction
For the construction of pSilencer-RPL15A and pSilencer-
RPL15B, two pairs of oligonucleotides were respectively
synthesized as follows: P1: 5'-GAT CCA GAA GCA GTC
TGA TGT CAT TAC AAG AGA ATG ACA TCA GAC TGC
TTC TTT TTT TGG AAA-3'; P1': 5'-AGC TTT TCC AAA AAA
AGA AGC AGT CTG ATG TCA TTC TCT TGT AAT GAC
ATC AGA CTG CTT CTG-3'; P2: 5'-GAT CCG GTT ACG
TTA TAT ATA GGA TTC AAG AGA TCC TAT ATA TAA CGT
AAC CTT TTT TGG AAA-3'; P2': 5'-AGC TTT TCC AAA AAA
GGT TAC GTT ATA TAT AGG ATC TCT TGA ATC CTA TAT
ATA ACG TAA CCG-3'. The two oligonucleotides were
annealed and cloned into pSilencer3.0 (Ambion, Austin,
TX), respectively. The insert sequences were confirmed by
DNA sequencing.
Cell transfection
Cell transfection were performed with Lipofectamine
2000 (Invitrogen, Carlsbad, CA) as described in the man-
ufacturer. Briefly, SGC7901 cells were plated and grown to
80–90% confluence without antibiotics. Then they were
transfected with 1 µg siRNA expressing vector pSilencer-
RPL15A or pSilencer-RPL15B. After 24 h of transfection,
G418 (400 µg/ml) was added into cells for stable screen-BMC Cancer 2006, 6:91 http://www.biomedcentral.com/1471-2407/6/91
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ing. The mixed clones were expanded for an additional 2
months. Cells transfected with pSilencer-RPL15A, pSi-
lencer-RPL15B or empty vector pSilencer3.0 were desig-
nated as SGC7901-L15AsiRNA, SGC7901-L15BsiRNA
and SGC7901-pcDNA respectively.
Western blot
Cells grown to 70–90% confluence were collected by
scraping and washed with ice-cold PBS for two times. The
cell pellets or tissues were homogenized in extraction
buffer (50 mM Tris-HCl, 0.1%SDS, 150 mM NaCl, 100
µg/ml phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin,
1% NP-40, and 0.5% sodium orthovanadate), then incu-
bated at 4°C for 30 min, centrifuged 20 min at 12,000 g/
min. Concentration of total proteins in the supernatant
was quantified by Bradford assay. The total proteins (50–
100 µg/lane) were resolved in 8–12% SDS-polycrylamide
gels, then transferred onto nitrocellulose membrane (0.45
µm, Millipore, USA) in 25 mM Tris-base, 190 mM glycine,
and 20% methanol using a semi-dry blotter. Following
blocking with 8% fat-free milk and 0.1% Tween20 in TBS
for 2 h, the membrane was incubated with anti-RPL15,
anti-Cyclin D1(Neomarker, 1:200), anti-Cyclin B1(Neo-
marker, 1:200) and anti-β-actin(Sigma, 1:5000) at 4°C
overnight. After binding of horseradish peroxidase (HRP)-
coupled goat anti-mouse or goat anti-rabbit IgG (Santa
Cruz, 1:5000) at room temperature for 2 hours, antigens
were visualized by enhanced chemiluminescence (ECL-
kit, Santa Cruz Biotechnology). All results are representa-
tives of three independent experiments.
MTT assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide assay was performed to evaluate the speed of cell
proliferation as described before [11]. Briefly, log phase
cells were trypsinized into single cell suspension and pas-
saged into 96-well plates at a density of 1 × 103 cells/well.
The total volume of culture medium in each well was 200
µl. After 1 d, 2 d, 3 d, 4 d and 5 d of cell culture, MTT solu-
tion was added into each well. After 4 hrs, the supernatant
was carefully removed. 150 µl DMSO was used to dissolve
the crystals by agitation for 10 min. The absorbance at 490
nm (A490) of each well was read on a microplate reader
BP800 (BIOHIT). Each study was performed in quadrupli-
cate and repeated 3 times.
Flow cytometry
Cells in log phase were washed twice with PBS and fixed
with 70% ethanol, washed again, and resuspended at
37°C for 15 min in PI staining solution (PBS containing
0.1% (v/v) Triton X-100 (Sigma), 0.2 mg/ml Dnase-free
RNase A (Roche), and 20 µg/ml PI), prepared fresh daily.
1 × 104 cells were then analyzed for fluorescence intensity
by FACScan (BD Biosciences) using the CellQuest flow-
cytometric analysis software. Cell proliferation index is
calculated with the formula: PI (proliferation index) =
number of S, G2 and M stage cells/number of total cells
×100%. Each study was repeated 4 times.
Soft agar clonogenic assay
Anchorage-independent growth as a characteristic of in
vitro tumorigenicity was assessed by soft agar clonogenic
assay described previously [11]. Briefly, cells were
detached and plated in 0.3% agarose with a 0.5% agarose
underlay (1 × 103/well in 6-well plates). The number of
foci >100 µm in 10 randomly selected field was counted
under microscope after 20 days. Each study was per-
formed in triplicate and repeated 3 times.
Mouse experiments
Mice were handled using best humane practices and were
cared for in accordance with NIH Animal Care and Use
Committee guidelines. Cells were harvested from tissue
culture flasks using trypsin and resuspended in PBS. Mice
were injected subcutaneously with 2 × 106 cells in 0.1 ml
into the right upper back and raised in the following 30
days. The mice were then monitored for tumor volume,
overall health, and total body weight. The size of the
tumor was determined by caliper measurement of the
subcutaneous tumor mass. Tumor volume was calculated
according to the formula 0.5 × length × width2. Each
experimental group contained 6 mice. Two independent
experiments were performed and gave similar results.
Statistical analysis
Bands from Western blot or RT-PCR were quantified by
Quantity One software (BioRad). Relative protein or
mRNA levels were calculated by referring them to the
amount of β-actin. Numerical data are presented as the
mean ± SEM. The difference between means was per-
formed with Student's T test. Immunohistochemical
results were analyzed by Kruskal-Wallis rank test and the
Mann-Whitney U test. All statistical analyses were per-
formed using SPSS11.0 software (Chicago, IL, USA). p <
0.05 was considered as statistically significant.
Results
Expression of RPL15 in gastric cancer tissues and cell lines
To examine whether the RPL15 expression level is altered
in gastric cancer, the expression and subcellular localiza-
tion of RPL15 were studied in a set of gastric cancer
patient specimens derived from 23 normal gastric
mucosae (NG), 23 gastric cancer (GC) and 23 adjacent
nontumorous tissues (NT). RPL15 was found expressed
predominantly in the cytoplasm of cells in gastric mucosa
and cancer (Fig. 1). The RPL15 staining in epithelial cells
from both NG and NT samples were weak, and the aver-
age staining scores of NT was 2.8 ± 1.13, higher than 1.2
± 0.49 in NG (p < 0.05). The RPL15 staining in gastric can-
cer cells was consistently stronger than those of the NGBMC Cancer 2006, 6:91 http://www.biomedcentral.com/1471-2407/6/91
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Expression of RPL15 in normal gastric mucosa, gastric cancer and adjacent nontumorous tissues Figure 1
Expression of RPL15 in normal gastric mucosa, gastric cancer and adjacent nontumorous tissues. Immunohisto-
chemical staining was preformed to evaluate RPL15 expression in gastric carcinoma and normal gastric mucosa tissues (×200). 
(A) Well-differentiated gastric carcinoma; (B) Poorly-differentiated gastric carcinoma; (C) adjacent nontumorous tissue; (D) 
Normal gastric mucosa.BMC Cancer 2006, 6:91 http://www.biomedcentral.com/1471-2407/6/91
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and NT samples (Figs. 1A and 1B) with an average score
6.3 ± 2.90 (p < 0.01). To investigate if the RPL15 expres-
sion might be associated with the progression of gastric
cancer, the relationship between the RPL15 expression
levels and the clinicopathologic characteristics of different
gastric cancer patients was compared. The result showed
that RPL15 expression did not correlate with differentia-
tion grade, Tumor-Node-Metastasis stage, gross type, or
metastasis with a statistic p > 0.05 in each parameter (data
not shown). These results provide evidence that RPL15
expression level positively correlates with gastric cancer
onset but is not associated with the progressiveness of the
cancer.
Analysis of RPL15 expression in gastric cancer cells and 
tissues
Expression levels of RPL15 were examined by western blot
in the gastric cancer and adjacent normal tissues taken
from 12 patients (Fig. 2A). In 9 of the 12 cases or 75%
samples, RPL15 was found overexpressed in cancerous tis-
sues, consistent with the result from immunohistochem-
istry analysis. We further compared the relative RPL15
expression level in five different gastric cancer cell lines,
i.e., AGS, MKN45, MKN28, SGC7901, and KATOIII, with
that of the normal gastric cell line GES-1. Again, RPL15
was found expressed at a higher level in all five gastric can-
cer cell lines than in GES-1 cells (Fig. 2B). These results
suggest that RPL15 may have a role in gastric carcinogen-
esis.
Interference of RPL15 expression inhibited SGC7901 cell 
proliferation
To further analyze the involvement of RPL15 in gastric
cancer malignant phenotype, we took advantage of siRNA
technology. SGC7901 cells were transfected with pSi-
lencer-RPL15A, pSilencer-RPL15B or empty vector. After
G418 selection for 2 months, western blot analysis
revealed that the cell mixture transfected with pSilencer-
RPL15A instead of pSilencer-RPL15B showed substantial
reduction in RPL15 level (Fig. 3A).
We further investigate the effect of pSilencer-RPL15A
transfection on cell growth of gastric cancer. The result of
Western blot analysis of RPL15 expression in gastric cancer  tissues and cell lines Figure 2
Western blot analysis of RPL15 expression in gastric 
cancer tissues and cell lines. A, protein isolated from gas-
tric cancer and adjacent nontumorous tissues obtained from 
12 patients was separated by SDS-PAGE and subjected to 
western blot analysis using anti-RPL15 and anti-β-actin anti-
bodies. Four representative pairs of tissues are presented. N, 
normal tissue; T, gastric cancer tissue. B, GES-1 and five gas-
tric cancer cells were collected and lysed, then analyzed by 
Western blotting. The level of RPL15 expression was much 
higher in all five gastric cancer cell line than in GES-1.
Effect of RPL15 expression on cell proliferation Figure 3
Effect of RPL15 expression on cell proliferation. A, 
SGC7901 cells transfected with pSilencer-RPL15A, pSilencer-
RPL15B or empty vector were selected with G418 (400 ng/
ml) for 2 months. The mixed clones were used for analyzing 
the expression of RPL15, Cyclin B1 and Cyclin D1 by west-
ern blot. Anti-β-actin antibody was set as an internal control. 
B, Cell proliferation was determined by MTT assay. Cells sta-
bly transfected with pSilencer-RPL15A or empty vector were 
plated in quadruplicate in 96-well plates. At the indicated 
time intervals, the monolayer cells were processed for MTT 
assay and the absorbance was read at 490 nm in an enzyme-
linked immunosorbent assay reader. **p < 0.05 and *p < 0.01 
vs SGC7901 and SGC7901-pcDNA. C, cell cycle distribution 
of log-phase transfected cells was evaluated by FACScan. Cell 
proliferation index was calculated as described in Materials 
and Methods (low right panel). Each number represents 
mean ± SD of four different experiments. *p < 0.01 vs 
SGC7901 and SGC7901-pcDNA.BMC Cancer 2006, 6:91 http://www.biomedcentral.com/1471-2407/6/91
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MTT showed that SGC7901-L15AsiRNA cells grew signifi-
cantly slower than the control cells (SGC7901 and
SGC7901-pcDNA; Fig. 3B). Cell cycle analysis revealed
that the population of cells in the S+G2+M phase was
remarkably decreased by pSilencer-RPL15A expression
(31.1% of asynchronous SGC7901-L15AsiRNA cells in
the S+G2+M phase of the cell cycle compared with 41.1%
of control cells and 37.4% of SGC7901 cells, Fig. 3C). We
questioned if RPL15 promote cell cycle progress by chang-
ing the expression of cyclins. Western blot demonstrated
that neither expression of Cyclin D1 nor Cyclin B1 were
influenced by ectopic expression of RPL15 (Fig. 3A), indi-
cating there might be other molecules mediating the pro-
moting effect of RPL15 on cell proliferation of gastric
cancer.
Interference of RPL15 expression or activity inhibited 
tumorigenicity of SGC7901 Cells
Anchorage-independent growth could be a sensitive
marker for tumor growth in vivo; therefore, we examined
whether interference of RPL15 expression would cause an
inhibition of SGC7901 cell growth in soft agar. As shown
in Fig. 4, siRNA transfection resulted in a substantial
reduction in the colony number (5–9 colonies, respec-
Interference of RPL15 expression inhibits colony formation ofSGC7901 cells Figure 4
Interference of RPL15 expression inhibits colony formation ofSGC7901 cells. Cells were placed in media containing 
soft agar and incubated for 20 days. The number of foci >100 µm was counted in 10 random fields. Vertical bars (right panel) 
represent mean ± SD from three separate experiments, each conducted in triplicate. **p < 0.05 vs SGC7901 and SGC7901-
pcDNA.
Tumorigenicity ability of SGC7901 cells transfected with siRNA vectors. Tumorigenicity ability was evaluated by nude mice  assay Figure 5
Tumorigenicity ability of SGC7901 cells transfected with siRNA vectors. Tumorigenicity ability was evaluated 
by nude mice assay. Mice were injected subcutaneously with 2 × 106 transfected cells. After 1 month of cell injection, the 
volume of tumor was calculated (left panel) according to the formula 0.5 × length × width2. Two independent experiments 
were performed. *p < 0.05 vs SGC7901-pcDNA.BMC Cancer 2006, 6:91 http://www.biomedcentral.com/1471-2407/6/91
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tively) when compared with the control cells (SGC7901-
pcDNA and SGC7901, 25–35 and 28–39, both p < 0.01).
To confirm this effect in vivo, we injected subcutaneously
the siRNA expressing SGC7901 cells into the right upper
back of athymic nude mice to see if they might affect
tumor induction. Fig. 5 shows the relative tumor growth
for two cell lines. On experiment day 30, the average
tumor volume in control animals was 628.3 mm3 com-
pared to 157.4 mm3 in SGC7901-L15AsiRNA group.
Discussion
A ribosome is an organelle composed of rRNA and two
subunits, which can work together as a factory to translate
mRNA into a polypeptide chain during protein synthesis
in cell. In numerous cancers, it has been found that pro-
tein synthesis rates and the expression of several transla-
tion components are often significantly elevated,
indicating the potential importance of ribosome function
and translational control in tumor progression[12,13].
At present, approximately over 80 ribosomal proteins are
found to localize within the large and small subunits of
eukaryotic ribosomes[14]. Some of these ribosomal pro-
teins are differentially or ectopically expressed in cancer
cells as compared to normal cells. Kasai et al determined
the expression profile of 12 ribosomal proteins in colorec-
tal cancer and normal epithelia of human colorectal
mucosa using immunohistochemistry [15]. They found
that the expression of 10 ribosomal proteins (Sa, S8, S12,
S18, S24, L13a, L18, L28, L32 and L35a) were decreased
and 2 proteins (S11 and L7) were significantly enhanced
in colorectal cancers. Results of real time RT-PCR showed
that RPL44 mRNA was overexpressed in hepatocellular
carcinoma tissues and cell lines [16]. Additionally, expres-
sion of S8, L12, L23a, L27 and L30 ribosomal protein
mRNAs was up-regulated in human hepatocellular carci-
noma [17]. Another ribosomal protein gene ectopically
expressed in cancer is RPL14, transcriptional loss of which
was observed in lung and oral cancers [18]. All these data
indicated that the ectopic expression of ribosomal pro-
teins be a common phenomenon in the development of
cancer. In the present study, for the first time we reported
that RPL15 was highly expressed in gastric cancer tissues
and cell lines, indicating that RPL15 serve as a potential
marker for diagnosis of gastric cancer. It is becoming
increasingly clear that a growing number of ribosomal
proteins exhibit various secondary functions besides pro-
tein synthesis[12,13]. There have been many reports that
implicate ribosomal proteins in developmental or regula-
tory processes. There is evidence that ribosomal proteins
may be tumor suppressors, oncogenes and gene-specific
translational regulators. Roles for ribosomal proteins in
DNA repair and regulation of transcription have been pro-
posed [9,19] Ribosomal proteins are also involved in reg-
ulation of apoptosis. It has been reported that ribosomal
protein S29 induces apoptosis in non-small cell lung can-
cer cells by downregulation of Bcl-2, Bcl-XL and survivin
and upregulation of p53, and Bax [20]. And human ribos-
omal protein L13a also induces apoptosis, presumably by
arresting cell growth in the G2/M phase of the cell cycle
[21].
In the present study, we demonstrated that inhibition of
RPL15 expression could suppress the proliferation of gas-
tric cancer by in vitro and in vivo assay. These results sug-
gested that RPL15 promote the growth of gastric cancer,
similar to the results of Kim et al in liver cancer. They
reported an HCC-related gene, RPL44, which can
enhanced colony formation and cell proliferation of HCC
cells [16] However, no molecular mechanisms in detail
had been explored in both of these two studies. So further
work to elucidate why some ribosomal proteins can pro-
mote the proliferation of tumor cells should be done in
the future.
Conclusion
RPL15 is highly expressed in gastric cancer tissues and cell
lines. It plays a role in cell proliferation of gastric cancer.
So RPL15 may be a potential target for anticancer therapy
of gastric cancer.
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